DaVita's CFO indicated a significant drop in Medicare add-on payments for CorMedix's DefenCath starting Q2 2027, with continued low levels through the year. This negative outlook on reimbursement directly impacts CorMedix's pricing power and future revenue, leading to a nearly 26% stock decline.
DaVita's CFO, Joel Ackerman, disclosed during their Q3 earnings call that Medicare add-on payments for CorMedix's DefenCath are projected to significantly decrease from Q1 to Q2 2027 and remain low thereafter. This is critical because Medicare reimbursement levels directly dictate the pricing CorMedix can charge its dialysis center clients for DefenCath. The market reacted sharply, sending CorMedix shares down nearly 26% to a new 52-week low, as this outlook implies substantial future revenue headwinds beyond the previously guided 2026 transition. For traders, this presents a clear short-term negative catalyst for CRMD, with long-term revenue projections now under severe pressure, highlighting the risk associated with reliance on specific reimbursement mechanisms.